Research Progress on Drugs for Metabolic Dysfunction-associated Steatotic Liver Disease Under"Co-management of Fatty Liver and Diabetes"Model
10.3969/j.issn.1008-7125.2024.11.010
- VernacularTitle:基于"糖肝共管"模式代谢相关脂肪性肝病的药物研究进展
- Author:
Aifang LIU
1
;
Xinyong JIA
;
Lei LUO
;
Wenlong YANG
Author Information
1. 南昌大学第二附属医院感染性疾病科(330006)
- Publication Type:Journal Article
- Keywords:
Metabolic Dysfunction-Associated Steatotic Liver Disease;
Type 2 Diabetes Mellitus;
Co-Management;
Therapy
- From:
Chinese Journal of Gastroenterology
2024;29(11):697-701
- CountryChina
- Language:Chinese
-
Abstract:
In the context of the global epidemic of metabolic syndrome,the incidence of type 2 diabetes mellitus(T2DM)and metabolic dysfunction-associated steatotic liver disease(MASLD)is on the rise,with a close relationship between the two conditions.They often co-occur and are rapidly becoming a significant public health issue worldwide.In May 2024,the concept of"co-management of fatty liver and diabetes"was first introduced.To date,no approved medications for the treatment of T2DM combined with MASLD have been launched.This article reviewed the progress of MASLD treatment drugs within the"co-management of fatty liver and diabetes"model,providing clinical references for the treatment of T2DM combined with MASLD.
